GlassScriptPhysician profile
Tananarieve P Brown
NPI 1306175203
$4,942.62
in general payments reported to CMS, 2019-2025
17 companies · $918 in 2025
The $918 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,169 · 2022: $501 · 2023: $1,151 · 2024: $1,203 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,172 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,172.26 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $869.44 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $649.09 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $644.33 | 2021-2025 | Aristada, Lybalvi |
| Abbvie INC. | $634.89 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $432.13 | 2021-2025 | Invega Sustenna, Invega Trinza, Invega |
| E.R. Squibb & Sons, L.L.C. | $420.07 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $401.71 | 2021-2025 | Uzedy, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $337.49 | 2021-2025 | Ingrezza |
| Indivior INC. | $236.85 | 2021-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $107.80 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.26 | 2022-2024 | Trintellix |
| Axsome Therapeutics, INC. | $32.93 | 2024 | Auvelity |
| Lundbeck LLC | $30.18 | 2021-2023 | Rexulti |
| Gilead Sciences, INC. | $29.13 | 2023 | |
| Vanda Pharmaceuticals INC. | $28.96 | 2024 | Fanapt, Hetlioz |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $22.82 | 2024 | Xelstrym |
| Eisai INC. | $18.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tananarieve Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.